Gastric cancer and the epoch of immunotherapy approaches

Table 1 List of the anti-gastric cancer clinical trials using dendritic cells

Ref.	Title	Sponsor/collaborator	Status	Duration
Kono et al[132], Clin Cancer Res 2002	Dendritic cells pulsed with HER-2/neu-derived peptides can induce specific T-cell responses in patients with gastric cancer	Yamanashi Medical University Japanese Clinical Oncology Fund and from the Public Trust Haraguchi Memorial Cancer Research Fund	Completed published	NA
Sadanaga et al[133], Clin Cancer Res 2001	Dendritic cell vaccination with MAGE peptide is a novel therapeutic approach for gastrointestinal carcinomas	Medical Institute of Bioregulation, Kyushu University Japan Society for the Promotion of Science, Grant-in-Aid for Scientific Research (A) (08557074)	Completed published	Study started: January 1997 Completed: August 2000
http://www.clinicaltrials.gov/	A phase I study of active immunotherapy with carcinoembryonic antigen RNA-pulsed, autologous human cultured dendritic cells in patients with metastatic malignancies expressing carcinoembryonic antigen	Duke Cancer Institute NCI (NCT00004604)	Unknow1	Study first received: May 2, 2000 Last updated: December 13, 2011
http://www.clinicaltrials.gov/	A pilot study of active immunotherapy with HER2/neu intracellular domain protein-pulsed, autologous, cultured dendritic cells in patients with no evidence of disease after standard treatment for HER2/neu expressing malignancies	Duke Cancer Institute NCI (NCT00005956)	Unknow1	Study first received: July 5, 2000 Last updated: December 13, 2011
http://www.clinicaltrials.gov/	A phase I study of active Immunotherapy with autologous dendritic cells infected with CEA-6D expressing fowlpox -tricom in patients with advanced or metastatic malignancies expressing CEA	Duke Cancer Institute NCI (NCT00027534)	Completed	Study first received: December 7, 2001 Last updated: December 13, 2011
http://www.clinicaltrials.gov/	A Phase I clinical trial of mTOR inhibition with rapamycin for enhancing intranodal dendritic cell vaccine induced anti-tumor immunity in patients with NY-ESO-1 expressing solid tumors	Roswell Park Cancer Institute (NCT01522820)	Not yet recruiting	Study first received: January 25, 2012 Last updated: February 3, 2012

¹Indicates status has not been verified in more than two years. NA: Not availiable.